Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SXTC

China SXT Pharmaceuticals Inc

Apr 25 • 02:37PM ET

1.02

Dollar change -0.05
Percentage change -4.57	%

Healthcare • Drug Manufacturers - Specialty & Generic • China • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	3.13%	Shs Outstand	11.43M	Perf Week	3.14%
Market Cap	0.58M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.55M	Perf Month	-39.22%
Income	-14.14M	PEG	-	EPS next Q	-	Inst Own	1.62%	Short Float	11.57%	Perf Quarter	-46.26%
Sales	1.70M	P/S	0.34	EPS this Y	-	Inst Trans	-	Short Ratio	0.05	Perf Half Y	-64.30%
Book/sh	0.28	P/B	3.66	EPS next Y	-	ROA	-76.89%	Short Interest	0.06M	Perf Year	-78.73%
Cash/sh	20.12	P/C	0.05	EPS next 5Y	-	ROE	-141.60%	52W Range	0.94 - 9.38	Perf YTD	-74.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-262.37%	52W High	-89.11%	Beta	1.09
Dividend TTM	-	Quick Ratio	1.40	Sales past 5Y	-25.90%	Gross Margin	30.66%	52W Low	8.62%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	95.64%	Oper. Margin	-810.70%	RSI (14)	34.65	Volatility	15.57% 20.00%
Employees	78	Debt/Eq	0.62	Sales Y/Y TTM	-38.81%	Profit Margin	-830.10%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	1.07
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.25M	Price	1.02
SMA20	-29.70%	SMA50	-40.87%	SMA200	-60.93%	Trades		Volume	118,409	Change	-4.57%

Oct-26-23 04:05PM	China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire)
Oct-04-23 08:30AM	China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split (GlobeNewswire)
Aug-02-23 06:03AM	China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022) (Simply Wall St.)
May-10-23 08:00AM	China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule (GlobeNewswire) +6.05%
Mar-29-23 09:43AM	Insiders who placed huge bets on China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) earlier this year would be disappointed with the 12% drop (Simply Wall St.)
08:00AM	Loading…
Nov-07-22 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire)
May-18-22 12:30PM	China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split (GlobeNewswire) -27.93%
Mar-14-22 10:33PM	China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million (GlobeNewswire) -9.81%
Jan-20-22 12:30PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). (ACCESSWIRE)
10:45AM	China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment (GlobeNewswire)
Jan-18-22 07:46AM	China SXT Pharmaceuticals Shares Plunge On $3.5M Equity Raise Issued At Steep Discount (Benzinga) -58.77%
06:47AM	China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
Jan-14-22 05:43PM	China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
02:00PM	China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin (PR Newswire)
Dec-16-21 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
08:00AM	Loading…
Oct-18-21 08:00AM	China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection (PR Newswire) +9.59%
Feb-19-21 08:00AM	China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split (PR Newswire) -23.04%
Nov-26-20 08:16PM	Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy? (Insider Monkey)
Sep-09-20 09:00AM	NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement (PR Newswire) +6.93%
May-29-20 03:08PM	Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC) (Insider Monkey) -5.61%
Mar-16-20 09:00AM	China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government (PR Newswire) -11.45%
Jan-28-20 09:35AM	How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain? (Simply Wall St.) -13.50%
Jan-24-20 02:23PM	China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production (Business Wire)
Jan-16-20 08:00AM	China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory (PR Newswire) +6.98%
Jan-03-20 10:30AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
Dec-04-19 07:10AM	What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked? (Simply Wall St.)
Nov-14-19 11:30AM	Should You Worry About China SXT Pharmaceuticals, Inc.s (NASDAQ:SXTC) ROCE? (Simply Wall St.)
Sep-11-19 07:00AM	China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques (PR Newswire)
Aug-19-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019 (PR Newswire)
Aug-12-19 08:00AM	China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate (PR Newswire) +20.26%
08:00AM	Loading…
Jul-03-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production (PR Newswire)
May-22-19 11:20AM	China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province (PR Newswire)
Apr-17-19 09:00AM	China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing (PR Newswire) -11.72%
Apr-02-19 06:30AM	China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification (PR Newswire)
Mar-28-19 06:30AM	China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018 (PR Newswire)
Jan-30-19 02:25PM	4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19) (ACCESSWIRE) +43.81%
Jan-04-19 07:30AM	China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering (PR Newswire)

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SXTC

China SXT Pharmaceuticals Inc

Upgrade your FINVIZ experience